MAbImprove reviews the most advanced anti-CoVID-19 monoclonal antibodies

LabEx MAbImprove publishes an article analyzing the data available on therapeutic anti-Sars-CoV-2 antibodies, encouraging general practitioners to seize these new tools to fight the Covid-19 epidemic.

Read the article (in French) 

In this article, the table lists the properties of the antibodies authorized or close to being authorized, fig. 1 illustrates the binding of an antibody cocktail to the RBD domain of protein S, and fig. 3 illustrates the different ways for obtaining these antibodies.

See these data